


Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	137	ecotin	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:03
L2	9	1 same wound	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 10:55
L3	1	1 same skin	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:05
L4	0	ecotin and (asiaticoside or madecassic or asiatic or asiatic\$3)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:06
L5	0	ecotin and centell\$3	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 10:57
L6	12	1 and lotion	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:04
L7	5	ecotin.clm.	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:04
L8	0	1 same topical\$4	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:05

L9	85	1 and topical\$4	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:06
L10	47	9 and thrombosis	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:06
L11	1904	(asiaticoside or madecassic or asiatic or asiatic\$3)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:07
L12	0	11 same thrombosis	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 12:49
L13	28	11 and thrombosis	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:07
L14	23	13 and (skin or topical\$4 or ointment or cream or lotion or patch)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:38
L15	137	ecotin	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:38
L16	1	15 same collagen	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 11:38

L17	10	1 same thrombosis	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 12:50
L18	48	1 same (anti-coagula\$4 or anticoagula\$4 or coagulat\$4)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:06
L19	4	asiatic\$4 same (anti-coagula\$4 or anticoagula\$4 or coagulat\$4)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:02
L20	3802	"197525"	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:03
L21	0	20 and asiatica	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:04
L22	41	20 and nippon	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:04
L23	2	22 and centella	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:05
L24	2	1 near5 coagulat\$4	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	ON	2005/12/07 13:06

[Return to the USPTO NPL Page](#) | [Help](#)

Interface language:

English

Databases selected: Multiple databases...

My Research

[« Back to Results](#)

- [Create a web page](#) with links to your articles, searches, and publications.

Marked Documents

[Recent Searches](#) | [Visited Publications](#)

Marked Documents lets you save documents you find useful. To add documents to your marked items:

- With Results displayed—Select the check box to the left of a document title.
- With a document displayed—Select the "mark document" check box on the document display page.

Once you have documents marked, you can create your bibliography, email marked documents, export citations, or create a web page with links to your articles.

* The maximum number of documents you can save is 50:

Recent Searches

[Marked Documents](#) | [Visited Publications](#)

1. [\(lotion\) AND \(ecotin\)](#)
Database: Multiple databases...
Look for terms in: Citation and document text
Publication type: All publication types

[Set Up Alert](#)

0 results as of December 7, 2005

2. [\(cream\) AND \(ecotin\)](#)
Database: Multiple databases...
Look for terms in: Citation and document text
Publication type: All publication types

[Set Up Alert](#)

0 results as of December 7, 2005

Visited Publications

[Marked Documents](#) | [Recent Searches](#)

Visited Publications displays the publications that you have viewed during your session. To add publications:

- Enter a publication search.
- Click on publication titles to view details.
- Links to your recent searches will be included here.

Once you have items listed in your visited publication, you can create a web page with links to your publications.

[^ Back to Top](#)

Copyright © 2005 ProQuest Information and Learning Company. All rights reserved. [Terms and Conditions](#)

Text-only interface



=> d his full

(FILE 'HOME' ENTERED AT 11:32:28 ON 07 DEC 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 11:32:50 ON 07 DEC 2005
SEA CENTEL? ASIATIC? (S) THROMBOS?

3 FILE CABA
1 FILE CAPLUS
1 FILE DDFU
1 FILE DRUGU
0* FILE FEDRIP
3 FILE PASCAL

L1 QUE CENTEL? ASIATIC? (S) THROMBOS?

D RANK

FILE 'CABA, PASCAL, CAPLUS, DDFU' ENTERED AT 11:34:48 ON 07 DEC 2005

L2 8 SEA L1

L3 8 DUP REM L2 (0 DUPLICATES REMOVED)

D L3 1- ALL

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 11:40:44 ON 07 DEC 2005
SEA ECOTIN? (S) (CREAM? OR LOTION? OR OINTMENT?)

0* FILE DRUGU

Total triterpenic fraction of *Centella asiatica* in chronic venous insufficiency and in high-perfusion microangiopathy
Special issue: *Centella asiatica* in vascular diseases - new clinical applications in venous, microcirculatory and arterial disease.

AU Incandela, L.; Cesarone, M. R.; Cacchio, M.; Sanctis, M. T. de;
Santavenere, C.; D'Auro, M. G.; Bucci, M.; Belcaro, G.; de Sanctis, M. T.

CS Irvine² Vascular Laboratory, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Chieti, Italy.

SO Angiology, (2001) Vol. 52, No. Supplement 2, pp. S9-S13.
Publisher: Westminister Publications Inc. Roslyn
ISSN: 0003-3197

CY United States

DT Journal

LA English

ED Entered STN: 20030110
Last Updated on STN: 20030110

AB Total triterpenic fraction of ***Centella asiatica*** (TTFCA) is effective in improving venous wall alterations in chronic venous hypertension and in protecting the venous endothelium. TTFCA is active on connective tissue modulation, improves the synthesis of collagen and other tissue proteins by modulating the action of fibroblasts in the vein wall, and stimulates collagen remodelling in and around the venous wall. This is due to the modulating action of TTFCA on fibroblasts as shown by experiments on the growth of human embryonal fibroblasts. TTFCA has a moderate in-vitro and in-vivo stimulating effect on collagen synthesis and, at higher dosages, an inhibition on the synthesis of collagen and acid mucopolysaccharides. Studies have indicated the role of TTFCA on the synthesis of specific venous wall elements by cell cultures of human embryonal fibroblasts. The tissue-stimulating action is shown by the increased collagen production independent from the stimulation of cell proliferation (this differentiates the action of TTFCA from cell growth factors). TTFCA is active on the microcirculation in venous and diabetic microangiopathy. Signs and symptoms of venous hypertension and oedema are improved by treatment. The remodelling on collagen synthesis could be one of the possible mechanisms of actions of TTFCA in the remodelling of echolucent (soft; therefore, with risk of **thrombosis** and embolization) plaques at the carotid and femoral bifurcation. This compound is safe and well tolerated. In conclusion, several actions of TTFCA in vascular diseases makes the use of this compound very interesting in venous and arterial problems.

CC SS200 Non-food/Non-feed Plant Products; VV450 Animal and in-vitro Models for Pharmaceuticals (New March 2000)

SC 5C; CA; HE

BT *Centella*; Apiaceae; Apiales; dicotyledons; an